Table 4

Correlation of ETAR expression with DFST according to clinicopathological variablesa

Clinicopathological variablesETAR statusDFSTPb
Months (95% CI)
Tumor size
 ≤2 cmNegative97 (87–106)NSc; 0.141
Positive82 (66–98)
Tumor size
 >2 cmNegative82 (69–96)NS; 0.194
Positive67 (51–83)
Lymph node negativeNegative95 (85–104)NS; 0.424
Positive86 (72–101)
Lymph node positiveNegative80 (64–95)NS; 0.145
Positive61 (45–76)
Invasive ductalNegative88 (77–100)NS; 0.296
Positive74 (60–87)
Invasive lobularNegative73 (54–92)NS; 0.331
Positive90 (64–115)
SpecialNegative105 (94–116)0.003
Positive62 (40–84)
Histologic grade I–IINegative96 (87–93)0.046
Positive78 (64–93)
Histologic grade IIINegative71 (52–91)NS; 0.837
Positive67 (49–86)
ER positiveNegative96 (85–106)0.011
Positive71 (58–85)
ER negativeNegative76 (63–89)NS; 0.922
Positive75 (54–96)
PR positiveNegative95 (84–106)NS; 0.090
Positive79 (64–95)
PR negativeNegative76 (64–88)NS; 0.327
Positive66 (50–83)
Her-2/neu negativeNegative88 (80–97)0.035
Positive71 (58–83)
Her-2/neu positiveNegative79 (56–102)NS; 0.627
PositiveCensored
MIB-1 labeling index ≤20%Negative92 (82–102)0.002
Positive64 (50–78)
MIB-1 labeling index >20%Negative82 (65–99)NS; 0.503
Positive86 (68–104)
Lymphovascular invasion absentNegative93 (84–101)0.033
Positive75 (62–88)
Lymphovascular invasion presentNegative65 (41–88)NS; 0.965
Positive66 (44–88)
No inflammatory componentNegative90 (81–99)NS; 0.059
Positive75 (63–86)
Inflammatory componentNegative77 (40–115)0.045
Positive8
  • a Primary breast cancers only.

  • b χ2 test.

  • c NS, not significant.